Defining the Immunogenicity and Efficacy of a Durable BCG Vaccine Strategy Optimized for Preventing TB in Pediatric HIV Infection

确定针对儿童 HIV 感染中预防结核病而优化的持久 BCG 疫苗策略的免疫原性和功效

基本信息

项目摘要

PROJECT SUMMARY Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) remains a major cause of morbidity and mortality worldwide and HIV+ individuals are particularly susceptible. The only licensed TB vaccine is the live attenuated Bacillus Calmette-Guerin (BCG) that is given intradermally to infants. While BCG provides substantial protection against non-pulmonary TB in childhood, it has little impact on pulmonary TB rates in adults. Recent studies in macaques have elicited striking protection from TB by instead delivering BCG intravenously or mucosally. However, BCG can cause disease in immunosuppressed recipients, including HIV+ children. Recently, a more attenuated BCG strain, BCG𝚫1419c, has been shown to be safe in athymic mice, immunogenic in both mice and guinea pigs, and more efficacious than BCG in both murine and guinea pigs models of TB. In this proposal, we will use our pediatric Mauritian cynomolgus macaque (MCM) model of TB to test both BCG and BCG𝚫1419c when given by the more clinically translatable mucosal route. Using MCM 1-2 years of age more closely resembles the pediatric population currently targeted for BCG vaccination. We will characterize the immunogenicity of BCG and BCG𝚫1419c in these young MCM using a suite of powerful assays, including multiparameter flow cytometry, single cell RNAseq, serology, and epigenetic analysis. We will determine the protective efficacy of these vaccines by challenging the animals with virulent Mtb and then assessing protection using our well-established and quantitative PET/CT imaging, pathology, and Mtb burden measures. In Aim 2, we will use a similar approach to define the safety, immunogenicity and protective efficacy of both BCG and BCG𝚫1419c in SIV+ juvenile MCM, modeling HIV+ children who could most benefit from an improved TB vaccine. We will test our hypothesis that this more attenuated BCG𝚫1419c will be safe, immunogenic, and protect from Mtb when administered mucosally to juvenile MCM with and without pre-existing SIV infection. This multi-PI proposal assembles a team of three established scientists with complimentary expertise in the fields of TB, HIV and SIV, immunology, and pediatric infectious diseases. Furthermore, we already have an established productive and collaborative relationship, ensuring successful completion of this important project.
项目摘要 由结核分枝杆菌(Mtb)引起的结核病(TB)仍然是发病的主要原因, 艾滋病毒感染者和艾滋病病毒阳性者特别容易受到感染。唯一获得许可的结核病疫苗是 减毒卡介苗(BCG),用于婴儿皮内注射。虽然BCG提供了大量 虽然它在儿童时期对非肺结核的保护作用,但它对成人肺结核发病率的影响很小。最近 对猕猴的研究表明,通过静脉注射卡介苗或 粘膜的然而,BCG可导致免疫抑制接受者的疾病,包括HIV+儿童。 最近,一种更加减毒的BCG菌株BCG1419 c已被证明在无胸腺小鼠中是安全的, 在小鼠和豚鼠中均具有免疫原性,且在小鼠和豚鼠中均比BCG更有效 结核病模型在本提案中,我们将使用我们的结核病儿童食蟹猴(MCM)模型, 当通过临床上更易翻译的粘膜途径给药时,测试BCG和BCGβ1419 c。使用MCM 1-2 年龄更接近于目前针对卡介苗接种的儿科人群。我们将 使用一套强大的测定来表征BCG和BCGβ1419 c在这些年轻MCM中的免疫原性, 包括多参数流式细胞术、单细胞RNAseq、血清学和表观遗传学分析。我们将 通过用毒性结核分枝杆菌攻击动物来确定这些疫苗的保护效力, 使用我们完善的定量PET/CT成像、病理学和结核菌负荷评估保护作用 措施在目标2中,我们将使用类似的方法来定义安全性、免疫原性和保护效力 SIV+青少年MCM中的BCG和BCGβ1419 c,模拟HIV+儿童, 改进的结核病疫苗。 我们将检验我们的假设,即这种更减毒的BCGβ 1419 c将是安全的、免疫原性的,并保护免于 Mtb粘膜给药时,以青少年MCM与和不预先存在的SIV感染。这种多PI 一项提案组建了一个由三名在结核病、艾滋病毒和艾滋病领域具有互补专长的科学家组成的小组, SIV,免疫学,儿科传染病。此外,我们已经建立了一个 这是一个富有成效的合作关系,确保成功完成这一重要项目。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lishomwa C Ndhlovu其他文献

HIV-1 infection induces retrotransposition of LINE-1 elements
  • DOI:
    10.1186/1742-4690-6-s2-p43
  • 发表时间:
    2009-09-24
  • 期刊:
  • 影响因子:
    3.900
  • 作者:
    R Brad Jones;Keith E Garrison;Haihan Song;Anton Buzdin;Naveed Anwar;Duncan A Meiklejohn;Lishomwa C Ndhlovu;Douglas F Nixon;Mario A Ostrowski
  • 通讯作者:
    Mario A Ostrowski

Lishomwa C Ndhlovu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lishomwa C Ndhlovu', 18)}}的其他基金

Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence
IL-15 免疫疗法对组织特异性 CD8 T 细胞的影响,以减少中枢神经系统 HIV 储存库的播种和持久性
  • 批准号:
    10831170
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistence
IL-15 免疫疗法对组织特异性 CD8 T 细胞的影响,以减少中枢神经系统 HIV 储存库的播种和持久性
  • 批准号:
    10476697
  • 财政年份:
    2022
  • 资助金额:
    $ 82.62万
  • 项目类别:
HOPE - HIV Obstruction by Programmed Epigenetics
HOPE - 通过编程表观遗传学阻断 HIV
  • 批准号:
    10625421
  • 财政年份:
    2021
  • 资助金额:
    $ 82.62万
  • 项目类别:
HOPE - HIV Obstruction by Programmed Epigenetics
HOPE - 通过编程表观遗传学阻断 HIV
  • 批准号:
    10313946
  • 财政年份:
    2021
  • 资助金额:
    $ 82.62万
  • 项目类别:
HOPE - HIV Obstruction by Programmed Epigenetics
HOPE - 通过编程表观遗传学阻断 HIV
  • 批准号:
    10469610
  • 财政年份:
    2021
  • 资助金额:
    $ 82.62万
  • 项目类别:
Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比 HIV 相关认知功能障碍引起的阿尔茨海默病
  • 批准号:
    10569610
  • 财政年份:
    2020
  • 资助金额:
    $ 82.62万
  • 项目类别:
Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比 HIV 相关认知功能障碍引起的阿尔茨海默病
  • 批准号:
    10374058
  • 财政年份:
    2020
  • 资助金额:
    $ 82.62万
  • 项目类别:
Harnessing single cell epigenome-wide profiling of myeloid cells to compare and contrast Alzheimer's from HIV-associated cognitive dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比阿尔茨海默病与艾滋病毒相关的认知功能障碍
  • 批准号:
    10632875
  • 财政年份:
    2020
  • 资助金额:
    $ 82.62万
  • 项目类别:
Harnessing Single Cell Epigenome-wide profiling of Myeloid cells to Compare and Contrast Alzheimer's from HIV-Associated Cognitive Dysfunction
利用骨髓细胞的单细胞表观基因组分析来比较和对比 HIV 相关认知功能障碍引起的阿尔茨海默病
  • 批准号:
    10795252
  • 财政年份:
    2020
  • 资助金额:
    $ 82.62万
  • 项目类别:
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents
HIV SIV对青春期前结核分枝杆菌免疫中非常规T细胞的影响
  • 批准号:
    10582697
  • 财政年份:
    2019
  • 资助金额:
    $ 82.62万
  • 项目类别:

相似海外基金

Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
  • 批准号:
    10755168
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
  • 批准号:
    480840
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
    Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
  • 批准号:
    10678157
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
  • 批准号:
    10744412
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
  • 批准号:
    23K07305
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
  • 批准号:
    23H02874
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
  • 批准号:
    10756652
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
  • 批准号:
    10730872
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
  • 批准号:
    10650648
  • 财政年份:
    2023
  • 资助金额:
    $ 82.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了